Follow

BioStock: Coegin Pharma seeks new opportunities through merger

01 March 2022 - 08:33

Coegin Pharma has announced successfully completing the merger acquisition of Lund-based diabetes company Follicum. The company, currently conducting a phase I/II trial with lead candidate AVX001 in actinic keratosis and preclinical development of AVX420 in leukemia and chronic kidney diseae, is grabbing the opportunity to strengthen its drug development portfolio by putting strong focus on diabetes complications. BioStock was able to get in touch with Professors Anna Hultgårdh and Jan Nilsson, two internationally-recognised experts in diabetes complications to learn more about what the acquisition will mean for Coegin going forward.

Read the interview with Professors Anna Hultgårdh and Jan Nilsson at biostock.se:

https://www.biostock.se/en/2022/03/coegin-pharma-seeks-new-opportunities-through-merger/

This is a press release from BioStock - Connecting Innovation & Capitalhttps://www.biostock.se/

Provided by: Cision
NGM Nordic SME (Sweden)
Coegin Pharma AB
Coegin Pharma specializes in molecular therapy which is further used in therapeutic treatments. Examples of diseases for which the company's solutions are used include cancer, leukemia and chronic kidney disease....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More